Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
E: investors.relations@vivalis.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,910.50 | 348.80 | 4.61% |
| CAC 40 | 6,896.91 | 203.51 | -2.87% |
| DAX 40 | 19,670.88 | 609.38 | -3.00% |
| Dow JONES (US) | 40,608.45 | 62.52 | 0.15% |
| FTSE 100 | 7,705.87 | 204.66 | -2.59% |
| HKSE | 20,628.86 | 364.37 | 1.80% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,326.90 | 2,612.87 | 8.24% |
| NZX 50 Index | 12,183.27 | 376.72 | 3.19% |
| S&P 500 | 5,456.90 | 474.13 | 9.52% |
| S&P/ASX 200 | 7,708.90 | 333.90 | 4.53% |
| SSE Composite Index | 3,216.41 | 29.60 | 0.93% |